Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma
Crossref DOI link: https://doi.org/10.1007/s11060-014-1691-z
Published Online: 2014-12-19
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ney, Douglas E.
Carlson, Julie A.
Damek, Denise M.
Gaspar, Laurie E.
Kavanagh, Brian D.
Kleinschmidt-DeMasters, B. K.
Waziri, Allen E.
Lillehei, Kevin O.
Reddy, Krishna
Chen, Changhu
Text and Data Mining valid from 2014-12-19